Clearance of co-development and commercialization agreement with AstraZeneca and receipt by Innate Pharma of $250m initial payment

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma’s proprietary anti-NKG2A antibody, IPH2201 (see announcement press release as of April, 24, 2015), received HSR clearance . The companies will now begin to work together to accelerate and broaden the development of IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune.

On June 30, 2015, Innate Pharma received the initial payment of $250 million from AstraZeneca.